Epiretinal transplantation of human bone marrow mesenchymal stem cells rescues retinal and vision function in a rat model of retinal degeneration  by Tzameret, Adi et al.
Stem Cell Research 15 (2015) 387–394
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scrEpiretinal transplantation of human bone marrow mesenchymal stem
cells rescues retinal and vision function in a rat model of
retinal degeneration☆Adi Tzameret a, Ifat Sher a, Michael Belkin a, Avraham J. Treves b, Amilia Meir b, Arnon Nagler c,
Hani Levkovitch-Verbin d, Ygal Rotenstreich a,1, Arieh S. Solomon a,⁎,1
a Goldschleger Eye Research Institute, Sackler Faculty of Medicine, Tel Aviv University, Sheba Medical Center, Tel-Hashomer, Israel
b Center for Stem Cells and Regenerative Medicine, Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Israel
c Hematology Division, Sheba Medical Center, Tel-Hashomer, Israel
d Rothberg Ophthalmic Molecular Biology Laboratory, Goldschleger Eye Research Institute, Sackler Faculty of Medicine, Tel Aviv University, Sheba Medical Center, Tel-Hashomer, IsraelAbbreviations: AMD, age-related macular degenera
hBM-MSCs, human bone marrow mesenchymal stem c
PFA, paraformaldehyde; RCS, royal college surgeons; RP, r
pigment epithelium.
☆ Grant support: Claire and Amedee Maratier Institute
Visual Disorders, Sackler Faculty of Medicine, Tel-Aviv Un
⁎ Corresponding author at: Goldschleger Eye Research
52621, Tel-Hashomer, Israel.
E-mail address: asolomon@post.tau.ac.il (A.S. Solomon
1 Equal contribution.
http://dx.doi.org/10.1016/j.scr.2015.08.007
1873-5061/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 14 June 2015
Received in revised form 16 July 2015
Accepted 13 August 2015
Available online 20 August 2015
Keywords:
Epiretinal transplantation
Human bone marrow mesenchymal stem cells
RCS rats
Retinal degenerationVision incapacitation and blindness associated with incurable retinal degeneration affect millions of people
worldwide. In this study, 0.25 × 106 human bonemarrow stem cells (hBM-MSCs)were transplanted epiretinally
in the right eye of Royal College Surgeons (RCS) rats at the age of 28 days.
Epiretinally transplanted cells were identiﬁed as a thin layer of cells along vitreous cavity, in close proximity to
the retina or attached to the lens capsule, up to 6 weeks following transplantation.
Epiretinal transplantation delayed photoreceptor degeneration and rescued retinal function up to 20 weeks
following cell transplantation. Visual functions remained close to normal levels in epiretinal transplantation
rats. No inﬂammation or any other adverse effects were observed in transplanted eyes.
Our ﬁndings suggest that transplantation of hBM-MSCs as a thin epiretinal layer is effective for treatment of ret-
inal degeneration in RCS rats, and that transplanting the cells in close proximity to the retina enhances hBM-MSC
therapeutic effect compared with intravitreal injection.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Retinal and macular degenerative diseases affect millions of people
worldwide. Similar to other neurodegenerative diseases, there are no
effective treatments that can stop retinal degeneration or restore
degenerative retina. Recent advances in stem cell technology led to
development of novel cell-based therapies, some are already in phase
I/II clinical trials (Mu et al., 2014; Ng et al., 2014; Ramsden et al., 2013).
Studies from our group and others suggest that human bone
marrow-derived mesenchymal stem cells (hBM-MSC) may be a
promising source for retinal cell-based therapy. Transplanting thesetion; ERG, electroretinogram;
ells; ONL, outer nuclear layer;
etinitis pigmentosa; RPE, retinal
for the Study of Blindness and
iversity.
Institute, Sheba Medical Center,
).
. This is an open access article undercells in Royal College of Surgeons (RCS) rats, a widely used model of
dry age-related macular degeneration (AMD) and retinal degeneration,
delayed retinal degeneration and rescued retinal and visual functions
(Arnhold et al., 2007; Inoue et al., 2007; Lu et al., 2010; Tzameret
et al., 2014). Accumulating evidence support the notion that hBM-
MSCs act in a paracrinemanner, as the cells secrete trophic and survival
growth factors and cytokines, as well as protective and reparative
micro- and nano-lipid microvesicles (Baglio et al., 2012; Yu et al.,
2014). This hypothesis is supported by recent studies demonstrating
that conditioned media collected from cultures of human adult adipose
mesenchymal stem cells inhibited photoreceptor degeneration and
retinal dysfunction in a mouse model of light-induced retinal damage
(Sugitani et al., 2013; Tsuruma et al., 2014). Moreover, hBM-MSCs
display immunosuppressive capacities (Caplan, 2009; Corcione et al.,
2006; Oh et al., 2008; Sheng et al., 2008) and are potentially less immu-
nogenic than other sources of allogenic stem cells, as studies in animals
demonstrated no difference in graft survival regardless of immunosup-
pression (Lu et al., 2010). Furthermore, these cells offer the unique
possibility of autologous transplantation that is likely to be even less
immunogenic (Caplan, 2009).
Currently, one of the major challenges in stem cell-based therapy is
how to safely deliver effective doses of cells to the target posterior eyethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the unique anatomy and physiology of the eye. The current subretinal
injection method involves three port pars plana, vitrectomy and inser-
tion of a needle that penetrates the retina and, in doing so, detaches
the photoreceptor cell layer from the RPE forming subretinal ‘blebs’
(Lu et al., 2009). Limited volumes can be injected and therapeutic effect
is restricted to areas proximal to point of injection (Inoue et al., 2007; Lu
et al., 2009; Schwartz et al., 2012). Moreover, the subretinal surgery
raises a signiﬁcant safety issue, as the retinal architecture across the en-
tire retina in AMD and retinitis pigmentosa (RP) patients is fragile and
the surgery can induce mechanical damage, reactive gliosis, and loss
of function (Lin et al., 2009; Maguire et al., 2008; Nork et al., 2012;
Wright et al., 2010). These procedural effects were documented in a re-
cent gene therapy trial inwhich patients receiving a subretinal injection
under the foveal region lost retinal thickness and visual acuity (Jacobson
et al., 2012), suggesting that subretinal surgery presents a signiﬁcant
risk in treating the fovea, the target tissue in AMD. Attempts to use scaf-
folds to facilitate subretinal cell transplantation as a thin layer resulted
in traumatic subretinal insertion and additional inﬂammation due to
scaffold degradation (Liu et al., 2014).
We have recently developed a new cell delivery system that enabled
the transplantation of hBM-MSCs as a thin layer across the extravascular
spaces of the choroid in RCS rats. The graft covered most of the area of
the back of the eye via a single injection with no retinal detachment
or choroidal hemorrhages. Cell transplantation delayed photoreceptor
degeneration throughout the whole retina and rescued retinal function
for up to 5months in RCS rats (Tzameret et al., 2014). By contrast, when
hBM-MSCs were injected intravitreally, they formed a large cell clamp
in the vitreous cavity and retinal function was rescued for a shorter du-
ration, up to 12weeks following transplantation (Tzameret et al., 2014).
These ﬁndings suggested that the delivery method signiﬁcantly affects
therapeutic potential of transplanted cells, and that graft location,
distance from the retina and graft surface area may be critical parame-
ters for achieving effective treatment.
In the present study we examined another delivery method for
hBM-MSCs to the posterior eye: transplanting the cells in the epiretina.
Transplantation of hBM-MSCs using this method resulted in photore-
ceptor rescue across most of the retina and signiﬁcantly enhanced
retinal function for up to 5 months following cell transplantation.
2. Methods
2.1. Animals
The pigmented RCS strainwas used in this study (D'Cruz et al., 2000;
Edwards and Szamier, 1977). Rats were born and bred in the Sheba
Medical Center animal facility under dim cyclic light (12 h at b5 lx,
12 h in the dark). All animal procedures and experiments were
conducted with approval and under the supervision of the Institutional
Animal Care Committee at the Sheba Medical Center, Tel-Hashomer,
and conformed to recommendations of the Association for Research in
Vision andOphthalmology Statement for theUse of Animals inOphthal-
mic and Vision Research.
2.2. Cell preparation
Primary human bone marrow mesenchymal stromal cell cultures
were derived from three healthy volunteers (ages 35–50 years). Bone
marrows were collected in the operating room under sterile conditions.
The research was approved by the institutional review board at the
Sheba Medical Center, Tel Hashomer. Bone marrow mononuclear cells
were separated by Ficoll gradient (1.077 g/dl) according to the
manufacturer instructions and were seeded in tissue culture ﬂasks
with culture media containing low-glucose Dulbecco's Modiﬁed Eagle's
Medium (DMEM) supplemented with 15% FCS, 100 U/ml penicillin,
100 ug/ml streptomycin and 2 mM L-glutamine. Tissue culture mediawas changed after 48 h and then twice a week until 70–80% conﬂuence
was reached, within 8–10 days. Cells were monitored for viability by
trypan blue staining before transplantation. For immunophenotype
analysis, cells were labeled with ﬂuorescein isothiocyanate (FITC),
phycoerythrin (PE) or allophycocyanin (APC)— conjugatedmonoclonal
antibodies in 100 μl phosphate buffer for 15min at room temperature or
30 min at 4 °C (Tzameret et al., 2014). Antibodies used were anti-
CD14, CD34, CD45, CD90 and CD105 (from eBioscience) and anti-
CD73 (from R&D Systems). Cultured cells were extensively washed
and resuspended in PBS with 0.5% FBS, passed through a 70 μm ﬁlter
and analyzed for surface marker proﬁle by ﬂow cytometry
(FACSCalibur-Becton, Dickinson). Proliferation Index was tested
within the ﬁrst 72 h after seeding by XTT reagent according to the
manufacturer instructions (Biological industries - Beit Haemek,
Israel). For Colony Forming Unit-Fibroblasts (CFU-F) assay, the
number of colonies produced in each passage per 100 cells was deter-
mined. Cells were seeded in 24 wells plate and incubated in a 5% CO2
95% room air humidiﬁed incubator. Colonies were formed, analyzed
and counted within 7–14 days after ﬁrst seeding. Cells were washed
to remove non-adherent colonies. Colonies were ﬁxed with 1 ml meth-
anol, stained with Giemsa stain, and manually counted. Cells were rou-
tinely tested forMycoplasma contamination using EZ-PCRMycoplasma
Test Kit (Biological industries - Beit Haemek, Israel).
2.3. Epiretinal cell transplantation
Human BM-MSCs were transplanted in the epiretina of RCS rats
(n = 22) at 28 days postnatal (designated week 0, W0), an age pre-
ceding major onset of retinal degeneration. Cells were prelabeled
with the lipophilic membrane stain 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiI), according to manu-
facturer instructions (Invitrogen). Rats were under xylazine
(10 mg/kg) and ketamine (75 mg/kg) intraperitoneal anesthesia.
Cell transplantation was performed under a surgical microscope
(Leica Wild M690; Wild Herring, Herring, Switzerland).
0.25 × 106 cells in 5 μl were transplanted epiretinally with a dispos-
able insulin syringe of 0.3 ml volume, 0.30 mm (30G) × 8 mm (BD
Micro-Fine Plus, Becton Dickinson and Company, USA). Pupils were
dilated using Tropicamide 0.5% and Phenylephrine HCl diluted to 2%.
The syringe needlewas introducedwith its opening facing the retina
and close to it. The introduction of the needle at this side created sepa-
ration of the vitreous from the retina. Thus, the transplanted cells were
applied directly on the surface of the retina (Supplementary Fig. 1A–E).
2.4. Electroretinogram (ERG) recording
For dark-adapted ERG, rats were kept in total darkness for 12 h prior
to testing. Animals were anesthetized with intraperitoneal injection of
75 mg/kg Ketamine and 10 mg/kg Xylazine, pupils were dilated with
topical 1% tropicamide and the corneas kept moist with 2.5% hydroxy-
propyl methylcellulose. ERGs were recorded from both eyes simulta-
neously using golden wire loops on the corneas. A chloride silver
reference electrode was placed subcutaneously near the temporal can-
thus. The ground electrode was placed on the tail. For dark-adapted
ERG, responses were averaged with stimulus intervals of 1 to 30 s
depending on the stimulus light intensity. For light-adapted ERG, the
animals were light-adapted for 10 min prior to testing and responses
were averaged with stimulus intervals of 1 s.
2.5. Histology analysis
Rats were euthanized with CO2 and the eyes were removed, ﬁxed in
formalin and embedded in parafﬁn. Retinal cross sections (4 μm) were
cut along the vertical meridian of the eye through the optic nerve and
were stained with hematoxylin and eosin.
Fig. 1. Localization of hBM-MSCs two days following epiretinal transplantation. Cross sections of control, non-injected eye (A) and an eye 2 days following epiretinal transplantation of DiI-
labeled hBM-MSCs (red, B). C—High power image of the indicated area in panel B. Nucleiwere counterstainedwith DAPI and the graft is indicatedwith an asterisk (C). Scale bar: 1000 μm
(A, B), 200 μm (C). GC — ganglion cells; INL — inner nuclear layer; and ONL — outer nuclear layer.
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Eyes were removed and ﬁxed in 4% paraformaldehyde (PFA) for
24 h, followed by incubation with a solution containing 2% PFA and 5%
sucrose for 1 h. Then eyes were incubated in sucrose solutions (5%,
10%, 12.5%, and 15% sucrose) for 30 min each followed by incubation
in 20% sucrose for 16 h. Eyeswere embedded in 20% sucrose in optimum
cutting temperature (O.C.T, Sakura). Ten micrometer sections were cut
along the vertical meridian of the eye through the optic nerve, counter-
stained with 4′,6-diamidino-2-phenylindole (DAPI) and examined
under a ﬂuorescent microscope for detection of transplanted
Dil-positive cells. For detection of rhodopsin, parafﬁn sections were in-
cubated following citrate buffer antigen retrieval with anti-rhodopsin
antibody (RET-P1, Abcam) and Alexa Fluor® 488-AfﬁniPure Donkey
Anti-Mouse IgG antibody (Jackson Immuno Research). Following
counterstaining with DAPI, sections were examined and photographed
by a ﬂuorescent microscope (Olimpus BX51).2.7. Visual cliff avoidance assay
Visual cliff avoidancewasVisual cliff avoidancewas tested based on the
protocol reported by Glynn et al. (Glynn et al., 2003) with somemodiﬁca-
tions. Ratswere tested in an open Perspex box (80 cm×80 cm×40 cm)
thatwas positioned on the edge of a laboratory bench (70 cm above the
ﬂoor) so that 2/3 of the base covered the bench (‘bench side’) while 1/3
was suspended over the edge of the bench (‘cliff side’), creating the ap-
pearance of a cliff (Supplementary Fig. 2). A large-size paper with a
checkerboard pattern of black and white squares (2 cm × 2 cm eachsquare) was placed under the bench side of the box as well as on the
ﬂoor underneath the box to emphasize the cliff drop-off. The main
light source in the experimental room was dimmed. Rats were placed
on a small glass box (platform, size 19 × 14 × 6 cm) positioned in the
middle of the open Perspex box between the cliff side and the bench
side, allowing the rats to survey their surroundings before dismounting
the platform.
Rats' activity was recorded for 2 min for latency to dismount the
start platform and the direction of the ﬁrst foot off the platform (“cliff”
or “bench”). The trial was performed once for each animal, at the
indicated age.
2.8. Statistical analysis
MANOVA analysis was performed using SPSS for windows version
20.0. We conducted a 12 (time in weeks) × 5 (amplitude) × 2
(transplanted versus control) MANOVA with time in weeks and stimuli
amplitude deﬁned as within-subjects factors, transplanted versus con-
trol serving as a between-subjects factor, and the b-wave recordings
serving as dependent variables. Differences were considered signiﬁcant
if p b 0.05.
3. Results
3.1. Epiretinal transplantation of hBM-MSCs
DiI-prelabeled cells hBM-MSCs Cells were epiretinally transplanted
in the right eye of RCS rats. The left eye was untreated and served as
control. There was no bleeding throughout or following the surgical
Fig. 2. Localization of hBM-MSCs at different time points following epiretinal transplantation. Cross sections of eyes removedone (A–C), three (D–F), four (G–I) or six (J–L)weeks following
epiretinal transplantation of DiI-labeled hBM-MSCs (red). A, D, G, J — bright ﬁeld images; B, E, H, K — ﬂuorescent images; and C, F, I, L — merged images. Scale bar: 1000 μm.
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formed a thin multi-layered cluster along the epiretina (Fig. 1). At later
time points, the DiI-positive cells were identiﬁed in the vitreous cavity
as a thin layer of cells along vitreous cavity, in close proximity to the ret-
ina or attached to the lens capsule, up to 6 weeks following
transplantation (Fig. 2).
3.2. Epiretinal transplantation of hBM-MSCs enhances retinal function
To evaluate the therapeutic effect of epiretinal transplantation of
hBM-MSCs, ERG testing was performed, prior to- and every two
weeks following cell transplantation. ERG testing enables the direct de-
termination of photoreceptor (a-wave component) and second-order
neuron (b-wave component) function (Kofuji et al., 2000; Penn and
Hagins, 1969; Young et al., 2012). The function of cones and rods can
be assessed by performing the test under light or dark adaptation, re-
spectively (Wurziger et al., 2001; Young et al., 2012). RCS rats exhibit
a prominent b-wave and a smaller a-wave, and both components de-
crease with age, as retinal degeneration progresses (Bush et al., 1995).
Fig. 3 demonstrates themeanmaximal ERG b-wave measured in re-
sponse to light stimuli at different light intensities under dark and light
adaptation in rats transplanted with hBM-MSCs in one eye. A slight and
transient reduction in ERG b-wave amplitude was recorded in
transplanted eyes two weeks following cell transplantation. However,
at subsequent time points (4–20 weeks following transplantation)
both light- and dark-adapted b-wave recordings were signiﬁcantly
higher across light amplitudes in the transplanted eyes compared
with the contralateral non treated (control) eyes (all p's ≤ 0.05).
Speciﬁcally, no b-wave signals were observed 6 weeks followingtransplantation in control eyes, under either dark or light adaptation
conditions. By contrast, in treated eyes substantial ERG responses
were recordable and maximal ERG b-wave amplitude response was
68.08 μV ± 14 (mean ± SE, Fig. 3). Treatment beneﬁt was lost by
22 weeks following transplantation, as evident by the reduced b-wave
ERG responses in treated eye that did not signiﬁcantly differ from con-
trol eyes.
The mean maximal a-wave amplitudes were signiﬁcantly higher in
transplanted compared with control eyes in all time points between 4
to 16 weeks following cell transplantation (Fig. 4). ERG responses
(b-wave and a-wave) recorded in untreated eyes did not signiﬁcantly
differ from eyes injected with medium (Supplementary Fig. 3, all
p-values N0.05).
3.3. Epiretinal transplantation improves scores of rats in a visual cliff
avoidance test
Next, we evaluated the functional consequences of epiretinal trans-
plantation of hBM-MSCs on the rats' visual behavior. Taking advantage
of rats' innate aversion to depth, we evaluated depth perception using
a visual cliff apparatus (Supplementary Fig. 2).
To avoid memory effect, each animal was tested only once in a life
time. Animals were tested 6 weeks post-transplantation, since at this
time point a maximal difference in mean ERG b-wave was recorded
between transplanted and control eyes. As shown in Fig. 5, young rats
at age of 4 weeks dismounted the platform within 15.5 ± 2.36 s
(mean ± SE), and all of the rats dismounted the platform on the table
side. By contrast at age of 10 weeks, rats that were injected with medi-
um at the age of 4 weeks (control rats) demonstrated a prolonged
Fig. 3. Stemcell transplantation enhancedb-wave amplitude ERG responses.Meanmaximal b-wave amplitude ERG responses to lightﬂashes in increasing luminance levelswere recorded
following dark- (squares) or light (circle)-adaptation, in transplanted (closed) or control (open) eyes at indicated weeks (W) following transplantation. Data is presented as mean ± SE.
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p = 0.018 compared with the young rats) and 37.5% of them
dismounted to the cliff side (p = 0.02 compared with the young rats).
Rats that underwent epiretinal transplantation of hBM-MSCs at the
age of 4 weeks, demonstrated improved depth perception at age of
10 weeks (6 weeks following transplantation). These rats dismountedFig. 4. Stem cell transplantation enhanced a-wave amplitude ERG responses mean maxi-
mal a-wave amplitude ERG responses to light ﬂashes of 23.5 cd/m2were recorded follow-
ing dark-adaptation, before (W0) and on the indicated weeks (W) following epiretinal
transplantation. Data is presented as mean ± SE.the stage earlier as compared with control rats (within 16.1 ± 3.3 s,
p = 0.058) and no signiﬁcant difference was observed between rats
that underwent stem cell transplantation and 4 week old rats (p =
0.87). Moreover following stem cell transplantation, 12.5% of the rats
dismounted the stage to the cliff side (p = 0.02 compared with control
rats). These data suggest that epiretinal transplantation of hBM-MSCs
improved visual function in RCS rats.
3.4. Epiretinal transplantation of hBM-MSCs ameliorates photoreceptor
degeneration across most of the retina
In accordance with retinal and visual function rescue, histological
analysis of eyes removed at different time points following cell trans-
plantation revealed an extensive photoreceptor rescue across most of
the retina. Thus, 6 weeks following cell transplantation, retinas from
control eyes contained only a single photoreceptor cell layer in the
outer nuclear layer (ONL). By contrast, in hBM-MSC grafted eyes, the
ONL was 5 cell deep (Fig. 6A). Rescue of photoreceptors was evident
along the entire retina (Fig. 6B and data not shown). Twenty weeks fol-
lowing cell transplantation, retinas of control rats were dystrophic,
while in the grafted rats, there was an extensive photoreceptor rescue
along most of the retina, with 2 layers of cells in the ONL (Fig. 6A).
Concomitant with attenuation of ONL degeneration, staining
with antibody against rhodopsin revealed that epiretinal transplantation
Fig. 5. Epiretinal transplantation improves scores of rats in a visual cliff avoidance test. Latency to dismount the starting stage (A) and the percent of rats that took theﬁrst footstep over the
cliff side (B) in 4 week old (4 weeks) and 10 week old (10 weeks) rats injected with medium or following epiretinal cell transplantation of hBM-MSCs. Data is presented as mean ± SE.
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retina up to 20weeks following cell transplantation (Fig. 7). Rhodopsin-
stained outer segments were demonstrated in transplanted eyes
up to 20 weeks following cell transplantation. By contrasts,Fig. 6. Photoreceptor rescue along the entire retina following epiretinal transplantation of hB
control and transplanted eyes. Black lines emphasize ONL depth. Scale bar: 100 μm. INL
(B) Number of cell layers in ONLwas evaluated by nuclei counting of 4ﬁelds along the entire retalready at age of 6 weeks, the debris zone in control eyes was
more prominent, outer segments were no longer seen and a
strong aberrant accumulation of rhodopsin in rod cell bodies
was observed.M-MSCs. (A) H&E stained sections at 6 weeks and 20 weeks following transplantation in
— inner nuclear layer; ONL — outer nuclear layer; and RPE — retinal epithelial cells.
ina inH&E stained sections. Data is presented asmean±SD from2 eyes at each time point.
Fig. 7. Epiretinal transplantation of hBM-MSCs preserves rod cell structure. Rhodopsin
staining (green) and DAPI counterstaining (blue) in eyes removed 6 weeks and
20 weeks following transplantation. Scale bar: 20 μm. INL — inner nuclear layer; ONL —
outer nuclear layer; ROS — rod outer segments; and DZ— debris zone.
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In this study we show that epiretinal transplantation of hBM-MSCs
in RCS rats resulted in long-term preservation of retinal function and
signiﬁcantly delayed photoreceptor degeneration throughout the retina
for up to 5 months.
Conventional intravitreal injection of stem cells results in cell clumps
in the vitreous, since the enveloping membrane of the vitreous and its
high viscous quality prevent the stem cells from spreading on the sur-
face of retina and diffuse through the vitreous body.We have previously
demonstrated that transplanting hBM-MSCs in clamps in the vitreous
reduced their therapeutic effect, most likely since the secreted trophic
factors need to diffuse through the vitreous and may fail to reach effec-
tive dosage in the retina (Tzameret et al., 2014). By contrast, the surgical
procedure presented here involves vitreous separation from the retina
to overcome the physico-chemical properties of the vitreous, allowing
more effective cell diffusion and facilitating cell spreading in close
proximity to the retina. Thus the epiretinal transplantation method en-
hances the therapeutic effect of hBM-MSCs compared with intravitreal
injection.
The key feature in epiretinal transplantation is the transplantation of
cells in close proximity to the retina. The large graft surface area most
likely enhances the therapeutic effects of the exosomes and proteins
secreted by transplanted cells. Furthermore, the distribution of the
cells as a relatively thin cell layer could potentially increase host-graft
interaction.
Epiretinal transplantation of hBM-MSCs could be identiﬁed in the
vitreous cavity for at least 6 weeks following transplantation (Fig. 2).
By contrast when these cells were transplanted in the extravascular
spaces of the choroid, transplanted cells could be identiﬁed in the host
tissue only up to 2 weeks following transplantation (Tzameret et al.,
2014). Nevertheless, ERG recordings demonstrated similar therapeutic
effect that lasted 5 months following cell transplantation regardless of
the delivery method. These ﬁndings suggest that the exosomes, trophic
factors and immune systemmodulators secreted by the hBM-MSCs dur-
ing the ﬁrst two weeks following cell transplantation may be sufﬁcient
to slow down retinal degeneration for several months.The vitreous volume in the human eye is signiﬁcantly larger than
that of rats. Hence we predict that conventional intravitreal injection
of hBM-MSCs will be even less effective in patients than in the rats.
Currently there are four ongoing registered phase I/II clinical trials
using hBM-MSCs for retinal and macular degeneration. In three of
these trials cells are delivered by intravitreal injection [NCT01531348,
NCT01914913, NCT02016508] (ClinicalTrials.gov.2014). In the fourth
trial, different methods of cell injection are being compared
(retrobulbar, subtenon, intravitreal, intraocular, subretinal and intrave-
nous, [NCT01920867]) (ClinicalTrials.gov.2014). The results from these
studies have not been reported yet, but based on our ﬁndings we predict
that different delivery methods will affect the clinical outcome.
Epiretinal transplantation does not involve retinal detachment and
may cause less trauma to the retina as compared with subretinal cell
delivery. However vitreous detachment in patients causes increased
photopsias, ﬂoaters and increased risk of retinal detachment and
macular holes (de Smet et al., 2013;Witmer and Cohen, 2013). In future
studies we will examine the safety of this procedure in large animal
models that closely mimic the human eye.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.08.007.
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